This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process which may lead to differences between this version and the Version of Record. Please cite this article as doi: 10.1111/jgh.15107 This article is protected by copyright. All rights reserved. Macaluso Fabio (Orcid ID: 0000-0001-5128-3846) A Propensity Score Weighted Comparison of Vedolizumab and Adalimumab in Crohn’s Disease Authors: Fabio Salvatore Macaluso 1 , Marco Ventimiglia 1 , Walter Fries 2 , Anna Viola 2 , Aldo Sitibondo 2 , Maria Cappello 3 , Barbara Scrivo 3 , Anita Busacca 3 , Antonino Carlo Privitera 4 , Salvatore Camilleri 5 , Serena Garufi 5 , Roberto Di Mitri 6 , Filippo Mocciaro 6 , Nunzio Belluardo 7 , Emiliano Giangreco 7 , Carmelo Bertolami 8 , Sara Renna 1 , Rosalba Orlando 1 , Giulia Rizzuto 1 , Mario Cottone 1 , Ambrogio Orlando 1 ; Sicilian Network for Inflammatory Bowel Disease (SN-IBD) Institutions: 1 Inflammatory bowel disease Unit, A.O.O.R. “Villa Sofia-Cervello”, Palermo, Italy. 2 Inflammatory bowel disease Unit, A.O.U. Policlinico "G. Martino”, Messina, Italy. 3 Gastroenterology and Hepatology Unit, A.O.U. Policlinico “G. Giaccone”, Palermo, Italy. 4 Inflammatory Bowel Disease Unit, A.O. “Cannizzaro”, Catania, Italy 5 Gastroenterology Unit, A.O.O.R. “S. Elia- M. Raimondi”, Caltanissetta, Italy. 6 Gastroenterology and Endoscopy Unit, A.R.N.A.S. “Civico Di Cristina Benfratelli”, Palermo, Italy 7 Gastroenterology Unit, A.O. “Guzzardi”, Vittoria, Italy